72 results
8-K
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
organization and reallocate its resources to better align with its current strategic goals, including its current focus on pursuing strategic alternatives
8-K
EX-99.6
uexxbzlvk7owl gi
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
cftkflqu
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
wyera8rfilbp6
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
ppnvsklbd z3bc2six
10 Nov 22
Prospectus supplement
4:21pm
425
2hphzq3n
4 Oct 22
Business combination disclosure
4:04pm
8-K
EX-99.1
8ffk2e26uz
4 Oct 22
Kineta Appoints Keith Baker as Chief Financial Officer
4:01pm